Malaria ELISA Kit (DEIA1929)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

serum, plasma(citrate)
Species Reactivity
Intended Use
The Malaria ELISA Kit is intended for measurement of antibodies against Plasmodium in human serum or plasma (citrate).
Contents of Kit
Reagents supplied
1. Malaria Coated Wells
2. Sample Diluent***: 1 bottle
3. Stop Solution: 1 bottle
4. Washing Solution (20x conc.)*: 1 bottle
5. Malaria Conjugate**: 1 bottle
6. TMB Substrate Solution: 1 bottle
7. Malaria High Control***: 1 bottle
8. Malaria Calibrator Control***: 1 bottle
9. Malaria Low Control***: 1 bottle
* contains 0.1 % Bronidox L after dilution
** contains 0.2 % Bronidox L
*** contains 0.1 % Kathon

Materials supplied
1. 1 Strip holder
2. 1 Cover foil
3. 1 Test protocol
4. 1 distribution and identification plan
2°C - 8°C
General Description
The Malaria ELISA is a fast and sensitive enzyme immunoassay for measurement of specific IgG and IgM antibodies against Plasmodium spp. The microplate is coated with recombinant antigens of P. falciparum and P. vivax. P. ovale and P. malaria are also detected due to the antigenic similarity between the different Plasmodium species.
Reconstitution And Storage
The reagents are stable up to the expiry date stated on the label when stored at 2°C - 8°C.


Have you cited DEIA1929 in a publication? Let us know and earn a reward for your research.

Related Products

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Deep learning enabled multi-wavelength spatial coherence microscope for the classification of malaria-infected stages with limited labelled data size


Authors: Singla, Neeru; Srivastava, Vishal

Malaria is a life-threatening mosquito-borne blood disease and therefore, early detection is essential for health. The standard detection technique is a Giemsa-stained blood smear test, which requires a highly skilled technician. Automated classifications of different phases of malaria continue to be a challenge with limited label data, especially in the case of early trophozoite and late trophozoite or schizont phase where the sensitivity is lower. The aim of the study is to develop a fast, robust and fully automated malaria classification system with limited labeled data set by using a multi-wavelength based system and a pre-trained convolutional neural networks (CNNs). The multi-wavelength system improves the classification performance by increasing the training dataset. We also compare our customized CNN performance with other conventional CNNs and show that our network with a lesser number of layers has a comparable performance. We believe that our approach can be applied to other limited annotated biological datasets.

Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting


Authors: Kiguba, Ronald; Ndagije, Helen Byomire; Nambasa, Victoria; Manirakiza, Leonard; Kirabira, Elijah; Serwanga, Allan; Olsson, Sten; Speybroeck, Niko; Mukonzo, Jackson

Background Therapeutic ineffectiveness of artemisinin-based combination therapy (ACT) increases the risk of malaria-related morbidity and mortality, and raises healthcare costs. Yet, little has been done to promote the pharmacovigilance (PV) of ACT ineffectiveness in sub-Saharan Africa, particularly in Uganda. This study aimed to determine the extent and associated factors of the past 6 months reporting of suspected or confirmed ACT therapeutic ineffectiveness by healthcare professionals (HCPs), and difficulties and potential solutions to the PV of ACT therapeutic ineffectiveness. Methods Survey of 685 HCPs conducted using a self-administered questionnaire from June to July 2018 in a nationally representative sample of public and private health facilities in Uganda. HCPs disclosed if they had spontaneously reported ACT therapeutic ineffectiveness to appropriate authorities in the previous 6 months. Multivariable logistic regression models were used to identify determinants of past 6-months, HCP-reported ACT therapeutic ineffectiveness. Results One in five (20%, 137/685; 95% CI 17-23%) HCPs reported ACT therapeutic ineffectiveness to an appropriate authority in the previous 6 months. HCPs commonly reported ACT therapeutic ineffectiveness to immediate supervisors (72%, 106/147), mostly verbally only (80%, 109/137); none had ever submitted a written report of ACT therapeutic ineffectiveness to Uganda's National Pharmacovigilance Centre. Common difficulties of reporting ACT therapeutic ineffectiveness were: unavailability of reporting procedures (31%, 129/421), poor follow-up of treated patients (22%, 93/421) and absence of reporting tools (16%, 68/421). Factors associated with reporting ACT therapeutic ineffectiveness in the past 6 months were: hospital-status (vs other; OR = 2.4, 95% CI 1.41-4.21), HCPs aged under 25 years (OR = 2.2, 95% CI 1.29-3.76), suspicion of ACT therapeutic ineffectiveness in the past 4 weeks (OR = 2.3, 95% CI 1.29-3.92), receipt of patient-complaint(s) of ACT therapeutic ineffectiveness in the past 4 weeks (OR = 2.9, 95% CI 1.62-5.12) and HCPs from northern (vs central; OR = 0.5, 95% CI 0.28-0.93) and western (vs central; OR = 0.4, 95% CI 0.17-0.77) parts of Uganda. Conclusion One in five HCPs reported ACT therapeutic ineffectiveness, mostly verbally to supervisors. The existing adverse drug reaction (ADR)-reporting infrastructure could be leveraged to promote the PV of ACT therapeutic ineffectiveness.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket